Today: 30 June 2026
Lynas Rare Earths share price slides after ASX selloff — what to watch before Monday
8 February 2026
1 min read

Lynas Rare Earths share price slides after ASX selloff — what to watch before Monday

Sydney, Feb 8, 2026, 17:36 AEDT — The session wrapped up with the market now closed.

  • Lynas Rare Earths (ASX: LYC) slipped 3.2% to close at A$14.27 on Friday.
  • The S&P/ASX 200 dropped 2.0% in the previous session, dragging mining stocks lower.
  • Monday brings attention to rare-earths prices, any policy headlines, and how stable Lynas’ production remains.

Lynas Rare Earths Limited finished Friday at A$14.27, dropping 3.2%. Shares moved within a range of A$14.15 to A$14.73 as the session played out. ASX investors will watch for the next move when trading picks up on Monday.

Lynas stands out as the go-to liquid play for those aiming to gauge a “non-China” rare earths chain. But as soon as markets show any nerves, this trade’s once-clear direction gets murkier.

This comes right before a packed period for Australian stocks, as fund managers start zeroing in on cash flow, production numbers and forward guidance—details, not just the big picture. Lynas isn’t only about policy; there’s still the task of keeping plants running smoothly and making sure the price they get actually delivers.

Blame the wider mood: the S&P/ASX 200 closed out Friday off 2.03% at 8,708.80. Losses rippled through sectors, with commodity-linked names particularly vulnerable heading into the weekend.

Lynas shares haven’t caught a break. The stock ended Wednesday, Feb. 4 at A$16.01, then tumbled 7.9% on Thursday. Friday brought more selling, pushing it roughly 3.4% below where it closed back on Feb. 2.

Since its January update, the company hasn’t published any new disclosures. Lynas reported December quarter sales revenue up 43% to A$201.9 million, citing stronger selling prices that outpaced a drop in output caused by power outages at its Kalgoorlie facility in Western Australia.

NdPr, shorthand for neodymium and praseodymium, grabs the most attention from investors. The reason: it’s the key ingredient for high-strength permanent magnets found in electric motors and wind turbines. For Lynas, shifts in NdPr often trigger the quickest swings in sentiment.

Questions about management succession haven’t gone away. Back in January, Lynas announced that chief executive Amanda Lacaze would step down at the close of the financial year. Dylan Kelly, representing shareholder Terra Capital, described her track record as “spectacular,” according to remarks reported then. Reuters

Signals from abroad turned up mixed. In Friday’s U.S. session, MP Materials jumped roughly 8.4%. Rare-earths stocks aren’t tracking together across geographies at the moment.

There’s a risk the market hasn’t fully digested just how much operational hiccups could bite. Back in November, Lynas flagged the potential for a production shortfall at Kalgoorlie tied to power disruptions. The company also said it was racing to find off-grid power fixes.

The stock’s longer-term outlook is still tied to both policy moves and project progress. Lynas has pointed to uncertainty around its Seadrift heavy rare earths project in Texas, noting the company won’t move forward without a commercially viable offtake agreement.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • CELZ Jumps 252% as Creative Medical Technology Drops Equity Offer
    June 30, 2026, 12:50 PM EDT. Shares of Creative Medical Technology Holdings (NASDAQ:CELZ) shot up 252% Tuesday after the company pulled its June 25 S-1 for an equity and warrant deal. CELZ said it had not issued any shares under the canceled filing. Trading was heavy, hitting 146.1 million shares-almost 40 times its 3.7 million shares outstanding. The shelved offer would have meant 3.05 million new shares and warrants for another 6.09 million. CEO Timothy Warbington said they decided not to go ahead with the fundraising plan. Biotech ETFs didn't move much, pointing to a CELZ-specific jump. Still, analysts say cash remains tight, with limited room for rounds of regulatory approvals after December 2027.
Confluent stock edges higher as IBM deal vote nears after fresh merger filing
Previous Story

Confluent stock edges higher as IBM deal vote nears after fresh merger filing

US Economic Calendar Today: Stock Futures Hold Steady as Traders Eye Fed Speeches, Treasury Buyback and Delayed Jobs Data
Next Story

US Economic Calendar Today: Stock Futures Hold Steady as Traders Eye Fed Speeches, Treasury Buyback and Delayed Jobs Data

Go toTop